Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mateon Therapeutics Inc (MATN)

Mateon Therapeutics Inc (MATN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Mateon Therapeutics Inc 29397 AGOURA ROAD SUITE 107 AGUORA HILLS CA 91301 USA

www.mateon.com P: 650-635-7000

Description:

Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting the TGF-beta2 mRNA. Mateon is conducting a Phase 2/3 clinical trial of OT-101 in patients suffering from COVID-19. In addition, the company has initiated a global Phase 4 clinical trial of ArtiShield(TM) in India, Africa, and Latin America for the treatment of COVID-19, with results expected in the 4Q20. ArtiShieldTM received marketing approval from India.

Key Statistics

Overview:

Market Capitalization, $K 23,462
Shares Outstanding, K 90,240
Annual Sales, $ 0 K
Annual Net Income, $ -6,640 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,990 K
60-Month Beta 1.33
% of Insider Shareholders 39.22%
% of Institutional Shareholders 0.07%
Float, K 54,848
% Float 60.78%

Growth:

1-Year Return 53.85%
3-Year Return 4.50%
5-Year Return -67.50%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 04/05/21
Earnings Per Share ttm -0.02
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 12/28/12

MATN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -64.66%
Return-on-Assets % -42.92%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales 13.48
Price/Cash Flow N/A
Price/Book 1.47
Book Value/Share 0.18
Interest Coverage -7.85
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar